Business of LifeDr. Elizabeth Whelan, president of the American Council on Science and Health wonders why there is so little reporting of an already-existing drug which, if taken daily, might dramatically reduce the risk of breast cancer.
Dr. Peter Goss from Harvard is leading a group of US and Canadian scientists to recruit thousands of women at high risk of breast cancer to participate in a study of aromatase inhibitors.
this class of drugs — which includes Astra Zeneca's Arimidex and Pfizer's Aromasin — has already been shown, as Dr. Goss puts it, to "profoundly" reduce the risk of recurrence in women who have already been diagnosed and treated for breast cancer — and to do so with fewer side effects than an earlier drug, Tamoxifen. Arimidex decreases the chance of cancer developing in the other breast by almost 80 percent.UPDATE: If you had been reading the Cancer Blog, you would already know this and more Posted by Jill Fallon at April 1, 2005 05:49 PM | Permalink